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BACKGROUND
• Chronic spontaneous (also known as idiopathic) urticaria (CSU/CIU) is the occurrence of wheals (hives), angioedema or both for 6 weeks or longer due to known or unknown causes 1 • Although chronic spontaneous (idiopathic) urticaria (CSU/CIU) is not life threatening, it can significantly impact a patient's life when not adequately controlled by medication. Patients experience disturbing itch, sometimes pain, lack of sleep, occupational disabilities and social isolation, which results in a negative impact on their daily function, thus drastically lowering their health-related quality of life (HRQoL) [2] [3] [4] 
OBJECTIVE
• The ASSURE-CSU study is an observational, non-interventional, multinational, and multicenter study conducted in Canada, France, Germany, Italy, United Kingdom (UK), Spain and the Netherlands to identify and quantify the humanistic and economic burden of illness in CSU/CIU patients who are symptomatic despite treatment
• Here we present data on utility values among patients enrolled in Canada, Germany, UK, and the
Netherlands
METHODS
Study Design
• This study included a 1-year retrospective medical record abstraction, a cross-sectional patient reported outcomes survey, and a 7-day prospective patient diary
Patient Population
• Adult patients with a clinician-confirmed, guideline-defined diagnosis of CSU/CIU • Patients had received at least one treatment course with an H 1 -antihistamine • Patients had been symptomatic for more than 12 months at least 3 days per week and were currently symptomatic despite treatment
Outcomes
• EQ-5D-3L was completed by the patients at recruitment -EQ-5D-3L is a generic health status instrument which comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. A single utility score can be derived, with a maximum utility value of 1 (perfect health) and 0 (corresponding to death)
• Utility values were calculated and further stratified by disease severity defined by UAS7 scores • Urticaria severity was assessed prospectively over the 7 days following enrolment using a patient diary called Urticaria Activity Score. Twice-daily pruritus and hives ratings are averaged to create a daily UAS score which is summed over 7 days (UAS7) -UAS7 score ranges from 0 to 42 (highest severity)
• UAS7 scores were used to define categorical disease states as described previously ( 
RESULTS
• A total of 88, 98, 79 and 99 patients completed the patient survey in Canada, Germany, UK and the Netherlands, respectively
• The mean age of patients at enrolment ranged from 45 to 50 years and the majority of patients were women (70% to 80%)
EQ-5D utility score 
EQ-5D dimensions
• Among the different dimensions of EQ-5D, pain/discomfort was the most affected with 62.0%, 70.5%, 61.5% and 56.6% of patients reporting moderate to extreme problems, respectively (Figure 2) • The second most affected dimension was anxiety/depression for Canada, Germany and UK with 41.8%, 51.6% and 45.6% of patients reporting moderate to extreme problems, respectively. For the Netherlands, usual activities (44.4%) was the second most affected dimension (Figure 2 ) According to UAS7 disease health states
• With increasing severity of CSU/CIU, there was a consistent decrease in the mean utility scores (Figure 3) • Similarly, impact across all dimensions also increased with disease severity (Figure 4 ) 
CONCLUSIONS
• ASSURE-CSU is the first real-world international study reporting utility values in CSU/CIU using EQ-5D
• Utility scores were similar among countries and ranged from 0.71 to 0.76, suggesting that CSU/CIU can have a significant impact on patients' quality of life across countries
• EQ-5D dimensions reflecting symptoms (pain/discomfort), common comorbidities (anxiety and depression) and daily activities were most affected by CSU/CIU -Small variations in the percentage of patients reporting impact on the 3 dimensions were seen in the 4 countries
• The results indicate that there is an association between HRQoL, as measured by EQ-5D, and disease severity, as measured by UAS7. Therefore, improvements in UAS7 symptom scores due to treatment may improve HRQoL for CSU/CIU patients
